Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 May;6(3):202-11.e7.
doi: 10.1016/j.jalz.2010.03.007.

The Alzheimer's disease neuroimaging initiative: progress report and future plans

Michael W Weiner  1 , Paul S Aisen, Clifford R Jack Jr, William J Jagust, John Q Trojanowski, Leslie Shaw, Andrew J Saykin, John C Morris, Nigel Cairns, Laurel A Beckett, Arthur Toga, Robert Green, Sarah Walter, Holly Soares, Peter Snyder, Eric Siemers, William Potter, Patricia E Cole, Mark Schmidt; Alzheimer's Disease Neuroimaging Initiative
Affiliations
Review

The Alzheimer's disease neuroimaging initiative: progress report and future plans

Michael W Weiner et al. Alzheimers Dement. 2010 May.

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid beta (Abeta) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of Abeta and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall model of changes in the progression from normal aging to MCI to AD.
Fig. 2
Fig. 2
Patient recruitment sites in ADNI (provided by Sarah Walter at ADCS).
Fig. 3
Fig. 3
Governance and organization of ADNI.
Fig. 4
Fig. 4
Map showing all ADNI and ADNI-like efforts in the world (Figure kindly provided by Maria Carillo of the Alzheimer’s Association).
See this image and copyright information in PMC

References

    1. 2009 Alzheimer’s disease facts and figures. Alzheimers Dement. 2009;5:234–270. - PubMed
    1. Katzman R, Fox P. The world-wide impact of dementia. Projections of prevalence and costs. In: Mayeaux R, Christen Y, editors. Epidemiology of Alzheimer’s Disease: From Gene to Prevention. Berlin, Germany: Springer-Verlag; 1999. pp. 1–17.
    1. Acosta D, Wortmann M. In: Alzheimer’s Disease International World Alzheimer Report 2009. Prince M, Jackson J, editors. London, UK: Alzheimer’s Disease International; 2009. pp. 1–92.
    1. Khachaturian ZS. Diagnosis of Alzheimer’s disease: two-decades of progress. J Alzheimers Dis. 2006;9:409–415. - PubMed
    1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. - PubMed

List of all publications based on ADNI data

    1. Trojanowski JQ. Searching for the biomarkers of Alzheimer’s. Pract Neurol. 2004;3:30–34.
    1. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Alzheimers Dement. 2005;1:55–66. - PMC - PubMed
    1. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L. The Alzheimer’s Disease Neuroimaging Initiative. Neuroimaging Clin N Am. 2005;15:869–877. - PMC - PubMed
    1. Fukuyama H. Neuroimaging in mild cognitive impairment. Rinsho Shinkeigaku. 2006;46:791–794. - PubMed
    1. Iwatsubo T. Beta-and gamma-secretases. Rinsho Shinkeigaku. 2006;46:925–926. - PubMed

MeSH terms